PharmaGraphX

Log in Get Started

Ustekinumab

Steqeyma, Wezlana, Otulfi, Selarsdi, Pyzchiva, Yesintek, Imuldosa, Starjemza, Stelara

Uncategorized

Standard

Half-life

14.9-45.6 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Human monoclonal antibody binding shared p40 subunit of IL-12 and IL-23

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Plaque Psoriasis
·Psoriasis
·Ulcerative Colitis
·Crohn's Disease
·Chronic Plaque Psoriasis

Interactions

No curated interaction pairs are recorded for Ustekinumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nasopharyngitis
Upper respiratory infections
Headache
Fatigue

Pharmacokinetics

Half-life: 14.9-45.6 days
Protein binding: N/A

Pregnancy & lactation

Not recorded for Ustekinumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement